For the year ending 2025-12-31, SGP has $115,866K in assets. $10,166K in debts. $96,358K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 96,358 | |||
| Short-term investments | 11,078 | |||
| Other receivables | 431 | |||
| Prepaid expenses and other current assets | 901 | |||
| Total current assets | 108,768 | |||
| Other non-current assets | 492 | |||
| Property and equipment, net | 2,339 | |||
| Deferred offering costs | 2,715 | |||
| Right-of-use asset | 1,552 | |||
| Total assets | 115,866 | |||
| Accounts payable | 2,696 | |||
| Payroll-related accruals | 2,182 | |||
| Other current liabilities | 3,706 | |||
| Lease liability, current | 0 | |||
| Redeemable convertible preferred stock tranche liability | 0 | |||
| Total current liabilities | 8,584 | |||
| Lease liability, non-current | 1,582 | |||
| Total liabilities | 10,166 | |||
| Redeemable convertible preferred stock, .00001 par value 116,618,581 shares authorized, 20,341,968 and 9,608,914 shares issued and outstanding as of december 31, 2025 and 2024, respectively (aggregate liquidation preference of 200,878 and 73,542 as of december 31, 2025 and 2024, respectively) | 204,537 | |||
| Common stock, .00001 par value 154,383,336 shares authorized 2,203,620 and 2,196,423 shares issued and outstanding as of december31, 2025 and 2024, respectively | 0 | |||
| Common stock additional paid-in capital | 5,893 | |||
| Accumulated deficit | -104,730 | |||
| Total stockholders' deficit | -98,837 | |||
| Total liabilities, redeemable convertible preferred stock and stockholders' deficit | 115,866 | |||
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)